Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

122.81 +4.96 (+4.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
65 66 Next >
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
Tariffs could have big impact on earnings in 2025. 
Via Talk Markets
Topics Stocks / Equities
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
How Is The Market Feeling About Gilead Sciences?
 
Via Benzinga
16 Analysts Have This To Say About Gilead Sciences
 
Via Benzinga
Why Gilead Sciences Stock Is Jumping Today
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
From Gilead Sciences, Inc.
Via Business Wire
This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know. 
Via StockStory
Bullish Setups
You know things are bad when I stoop to offering some bullish setups, but that’s just where we’re at right now. 
Via Talk Markets
Topics Stocks / Equities
Robinhood, Gilead Sciences, Crocs, Lincoln Electric, HubSpot, GE HealthCare And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Moderna (MRNA) Q4 Earnings Report Preview: What To Look For
Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market open. Here’s what to expect. 
Via StockStory
Top S&P500 movers in Wednesday's session
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025. 
Via Benzinga
These S&P500 stocks have an unusual volume in today's session
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below. 
Via Chartmill
Why Gilead Sciences (GILD) Stock Is Trading Up Today
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the company reported impressive fourth-quarter results that exceeded analysts' revenue, EPS,... 
Via StockStory
These S&P500 stocks are moving in today's session
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday?
A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New... 
Via Benzinga
Topics Economy
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Discover the top S&P500 movers in Wednesday's pre-market session.
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session. 
Via Chartmill
Gilead Wins Price-Target Boosts After Solid Q4, Retail Brushes Off Medicare Reform Hit To HIV Drugs
Investors seem encouraged by the company's strong performance in its core business areas and the promise of further growth driven by its expanding pipeline. 
Via Stocktwits
Markets Mixed On Powell Testimony, Q4 Earnings
Market indexes were mixed today, after seeing all the majors in the red before the opening bell. The Dow closed up +123 points, +0.28%, while the S&P 500 squeaked by +2 points. 
Via Talk Markets
Topics Stocks Stocks / Equities
Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript
GILD earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Gilead Sciences Shares Push Higher After Q4 Report: Here's Why
Gilead Sciences reported its fourth-quarter financial results after Tuesday's closing bell. Here's a look at the highlights from the report: 
Via Benzinga
Gilead Sciences Beats Q4 EPS Forecast
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments. 
Via The Motley Fool
Gilead Sciences (NASDAQ:GILD) Delivers Strong Q4 Numbers
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 6.4% year on year to $7.57 billion. The company expects the full... 
Via StockStory
Gilead Outplays Veklury Downfall To Obliterate Forecasts. Will Shares Win Back Their Breakout?
Gilead obliterated fourth-quarter expectations Tuesday and issued an upbeat profit outlook for 2025. 
Via Investor's Business Daily
Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
65 66 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.